載入中
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
前收盤價
US$0.276
−US$0.034 · -10.97%
盤中時間採用ET。市場資料可能有所延遲。
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
日內區間
目前US$0.276
52週區間
目前US$0.276
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
60
合理估值
情緒
51
多空交錯
風險
71
高風險
動能
21
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
日內區間
目前US$0.276
52週區間
目前US$0.276
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 409.4萬 USD | 1418.1萬 USD | 3304.6萬 USD | 3475.4萬 USD | 2572.8萬 USD |
| 銷售、一般及管理費用 | 1220.8萬 USD | 1364.3萬 USD | 1979萬 USD | 1367.5萬 USD | 1115.3萬 USD |
| 營業費用 | 1280.3萬 USD | −7298.5萬 USD | 3.48億 USD | 4842.9萬 USD | 6584.7萬 USD |
| 折舊和攤銷 | 7.8萬 USD | 9.7萬 USD | 9.9萬 USD | 6.8萬 USD | 3000 USD |
| 營業利益 | −1280.3萬 USD | 7298.5萬 USD | −3.48億 USD | −4842.9萬 USD | −6584.7萬 USD |
| 淨利 | −3922.2萬 USD | 4200.5萬 USD | −3.85億 USD | −5255.6萬 USD | −5563.7萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM
State Street SPDR S&P Emerging Markets Small Cap ETFEWX
Vanguard Extended Market ETFVXFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
